Log in

OTCMKTS:RGRXRegeneRx Biopharmaceuticals Stock Price, Forecast & News

$0.34
+0.05 (+15.52 %)
(As of 06/1/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.24
Now: $0.34
$0.35
50-Day Range
$0.21
MA: $0.26
$0.30
52-Week Range
$0.10
Now: $0.34
$0.35
Volume627,467 shs
Average Volume80,200 shs
Market Capitalization$44.70 million
P/E RatioN/A
Dividend YieldN/A
Beta0.81
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4 (Tß4), for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. It also evaluates the commercial development of peptide fragments and derivatives of Tß4 for potential cosmeceutical and other personal care uses. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was founded in 1982 and is headquartered in Rockville, Maryland.
Read More
RegeneRx Biopharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.56 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:RGRX
CUSIPN/A
Phone301-208-9191

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$80,000.00
Book Value($0.02) per share

Profitability

Net Income$-1,400,000.00
Net Margins-1,910.16%

Miscellaneous

Employees3
Market Cap$44.70 million
Next Earnings Date6/3/2020 (Estimated)
OptionableNot Optionable

Receive RGRX News and Ratings via Email

Sign-up to receive the latest news and ratings for RGRX and its competitors with MarketBeat's FREE daily newsletter.

RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) Frequently Asked Questions

How has RegeneRx Biopharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

RegeneRx Biopharmaceuticals' stock was trading at $0.2049 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, RGRX shares have increased by 63.5% and is now trading at $0.3350. View which stocks have been most impacted by Coronavirus.

When is RegeneRx Biopharmaceuticals' next earnings date?

RegeneRx Biopharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, June 3rd 2020. View our earnings forecast for RegeneRx Biopharmaceuticals.

Has RegeneRx Biopharmaceuticals been receiving favorable news coverage?

Headlines about RGRX stock have been trending very positive recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. RegeneRx Biopharmaceuticals earned a news impact score of 3.5 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutRegeneRx Biopharmaceuticals.

Who are some of RegeneRx Biopharmaceuticals' key competitors?

What other stocks do shareholders of RegeneRx Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RegeneRx Biopharmaceuticals investors own include Inpixon (INPX), Biocept (BIOC), Pharmacyte Biotech (PMCB), SANUWAVE Health (SNWV), Sierra Oncology (SRRA), Ampliphi Biosciences (APHB), AVEO Pharmaceuticals (AVEO), Biopharmx (BPMX), Co-Diagnostics (CODX) and Cytori Therapeutics (CYTX).

Who are RegeneRx Biopharmaceuticals' key executives?

RegeneRx Biopharmaceuticals' management team includes the following people:
  • Dr. Allan L. Goldstein, Founder, Chairman, Chief Scientific Officer & Chairman of Scientific Advisor Board (Age 81)
  • Mr. J. J. Finkelstein, Pres, CEO & Director (Age 67)
  • Mr. Dane R. Saglio, Chief Financial Officer (Age 61)
  • Dr. Nabila A. Turjman Ph.D., Exec. Director of Regulatory Affairs

What is RegeneRx Biopharmaceuticals' stock symbol?

RegeneRx Biopharmaceuticals trades on the OTCMKTS under the ticker symbol "RGRX."

How do I buy shares of RegeneRx Biopharmaceuticals?

Shares of RGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is RegeneRx Biopharmaceuticals' stock price today?

One share of RGRX stock can currently be purchased for approximately $0.34.

How big of a company is RegeneRx Biopharmaceuticals?

RegeneRx Biopharmaceuticals has a market capitalization of $44.70 million and generates $80,000.00 in revenue each year. RegeneRx Biopharmaceuticals employs 3 workers across the globe.

What is RegeneRx Biopharmaceuticals' official website?

The official website for RegeneRx Biopharmaceuticals is www.regenerx.com.

How can I contact RegeneRx Biopharmaceuticals?

RegeneRx Biopharmaceuticals' mailing address is 15245 SHADY GROVE ROAD SUITE 470, ROCKVILLE MD, 20850. The biopharmaceutical company can be reached via phone at 301-208-9191 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.